MET and cancer: It was noteworthy that HGF-c-MET signaling pathway is activated in a range of cancer types including gastric cancer, colorectal cancer, head and neck cancer, hepatocellular carcinoma, lung cancer, urothelial carcinoma of bladder, glioblastoma, melanoma and ovarian cancer, among others 2, 4-11, and associated with an aggressive phenotype and poor prognosis in pancreatic cancer 12.